Altamira Therapeutics Ltd - CYTO Net Sales Margin

Graphic logo of altamiratherapeutics.com (CYTO)

Altamira Therapeutics (CYTO) operates in a stable environment due to the humanitarian status of biomedicine, which neutralizes external conflicts. The net profit margin demonstrates effective cost management, where 0.00 reflects the baseline level of the metric. Profitability is based on the advantageous licensing of unique RNA platforms, although the operational component relies on third-party CRO and CMO contractors.

altamiratherapeutics.com (CYTO) Return on Sales by Net Profit: for the period 07/04/2022 - 01/04/2025

altamiratherapeutics.com (CYTO) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Initial company analysis:altamiratherapeutics.com, CYTO
Manufactured product of Altamira Therapeutics

The selection of high-quality issuers is based on a rigorous analysis of fundamental efficiency multiples. This metric determines the share of net profit in every dollar of revenue, reflecting the final profitability of the business. For Altamira Therapeutics (CYTO), low pricing power in the over-the-counter segment limits the growth of this value. The absence of patent income creates additional pressure on earnings. The net profit margin trend allows for an objective assessment of the company's operational resilience.

Who Altamira Therapeutics competes with

HLN: Net Sales Margin|Net Return on Sales KVUE|Net Margin veronapharma.com|Net Return on Sales MENS (Jyong Biotech Corp)|Net Margin Ligand (LGND)|Net Sales Margin amneal.com (AMRX)|Net Sales Margin PRGO (perrigo.com)|Alvotech SA (ALVO) - Net Margin|Liquidia Inc. - Net Sales Margin|Net Profitability Margin Galapagos Corp (GLPG)|ANI Pharmaceuticals (ANIP) - Net Margin|Net Return on Sales MNKD|Net Margin Amphastar Pharmaceuticals, Inc.|Pacira Pharmaceuticals (PCRX) - Company Sales Margin|Net Sales Margin SPRY|TBPH - Net Margin|Aquestive Pharma - Return on Sales by Net Profit|Net Sales Margin scpharmaceuticals.com SCPH|Tectonic - Net Sales Margin|TNXP - Net Sales Margin|SXTC: Net Sales Margin|Eupraxia Pharma - Net Profit Rate|BHST (bioharvest.com) - Net Sales Margin|Net Return on Sales EXOZ (invizyne.com)|Net Sales Margin ORMP|Company Sales Margin Entera Bio|Net Sales Margin HYFT (MindWalk Holdings, Inc.)|ABVC BioPharma - Net Margin|Cumberland Corp - Net Sales Margin|QNTM - Net Sales Margin|FibroGen, Inc. (FGEN) - Net Margin|TELO: Company Net Profitability|RANI (Rani Therapeutics Inc) - Net Sales Margin|Net Margin synergychc.com SNYR|Net Margin Rallybio Corp. (RLYB)|LEXX - Net Margin|Net Sales Margin PULM (pulmatrix.com)|Company Net Profitability PTHL (Pheton)|APM - Net Margin|Company Sales Margin Lyra Therapeutics Inc LYRA|impactbiomedinc.com (IBO) - Net Margin|TNF Pharma (TNFA) - Net Sales Margin|YCBD (cbdmd.com) - Net Sales Margin|Return on Sales by Net Profit PainReform (PRFX)|Net Sales Margin LIPO|OPTN - Net Margin|Net Margin pieris.com PIRS|Net Profit Rate PROC|PTPI - Net Margin|Qilian International Holding (QLI) - Return on Sales by Net Profit|SLRN: Net Sales Margin|Return on Sales by Net Profit TFF Pharma